Kuwait Glp-1 Receptor Agonist Market Size & Outlook
Global Market
Related Markets
Kuwait glp-1 receptor agonist market highlights
- The Kuwait glp-1 receptor agonist market generated a revenue of USD 72.0 million in 2025 and is expected to reach USD 190.4 million by 2033.
- The Kuwait market is expected to grow at a CAGR of 11.7% from 2026 to 2033.
- In terms of segment, semaglutide (ozempic, wegovy, rybelsus) was the largest revenue generating product in 2025.
- Tirzepatide (Mounjaro, Zepbound) is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2025 | USD 72.0 million |
| Market revenue in 2033 | USD 190.4 million |
| Growth rate | 11.7% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (ozempic, wegovy, rybelsus) |
| Fastest growing segment | Tirzepatide (Mounjaro, Zepbound) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound), Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Others (Byetta, Bydureon, SOLIQUA) |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Novo Nordisk A/S ADR, AstraZeneca PLC |
Other key industry trends
- In terms of revenue, Kuwait accounted for 0.1% of the global glp-1 receptor agonist market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Middle East & Africa, Saudi Arabia glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2033.
- Saudi Arabia is the fastest growing regional market in Middle East & Africa and is projected to reach USD 1,248.1 million by 2033.
The GLP-1 receptor agonist market in Kuwait is expected to witness significant growth, driven by the high prevalence of diabetes and obesity. In 2021, Kuwait had around 803,000 adults with diabetes, with an age-adjusted prevalence of 24.9%. In addition, IGT affected around 582,000 people, and Impaired Fasting Glucose (IFG) was reported in 461,000 individuals. Diabetes-related mortality reached around 2,153 deaths.
The healthcare expenditure for diabetes was USD 1.5 billion. Type 1 diabetes cases included 0.4 per 1,000 children aged 0-14 years. The data highlights a growing diabetes burden, which is driving the demand for advanced treatment solutions.
Moreover, the high prevalence of diabetes in Kuwait and significant rates of IGT & IFG create a substantial opportunity for GLP-1 receptor agonists. These medications can help address the unmet need for effective diabetes management and glycemic control.
No credit card required*
Publish Date: Dec 23, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Glenmark Pharmaceuticals | View profile | 10001+ | Andheri, Maharashtra, India, Asia | www.glenmarkpharma.com |
Kuwait GLP-1 Receptor Agonist Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Receptor Agonist Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Ozempic, Wegovy, Rybelsus) was the largest segment with a revenue share of 88.89% in 2025.
Horizon Databook has segmented the Kuwait glp-1 receptor agonist market based on semaglutide (ozempic, wegovy, rybelsus), tirzepatide (mounjaro, zepbound), dulaglutide (trulicity), liraglutide (victoza, saxenda), others (byetta, bydureon, soliqua) covering the revenue growth of each sub-segment from 2021 to 2033.
The GLP-1 receptor agonist market in Kuwait is expected to witness significant growth, driven by the high prevalence of diabetes and obesity. In 2021, Kuwait had around 803,000 adults with diabetes, with an age-adjusted prevalence of 24.9%. In addition, IGT affected around 582,000 people, and Impaired Fasting Glucose (IFG) was reported in 461,000 individuals. Diabetes-related mortality reached around 2,153 deaths.
The healthcare expenditure for diabetes was USD 1.5 billion. Type 1 diabetes cases included 0.4 per 1,000 children aged 0-14 years. The data highlights a growing diabetes burden, which is driving the demand for advanced treatment solutions.
Moreover, the high prevalence of diabetes in Kuwait and significant rates of IGT & IFG create a substantial opportunity for GLP-1 receptor agonists. These medications can help address the unmet need for effective diabetes management and glycemic control.
- Kuwait Glp-1 Receptor Agonist Market Product Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Others (Byetta, Bydureon, SOLIQUA)
- Kuwait Glp-1 Receptor Agonist Market Application Outlook (Revenue, USD Million , 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity / Chronic Weight Management
- Cardiovascular Risk
- Kuwait Glp-1 Receptor Agonist Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Injectable / Parenteral
- Oral
- Kuwait Glp-1 Receptor Agonist Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to GLP-1 Receptor Agonist Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Receptor Agonist Market Outlook databook
- Our clientele includes a mix of GLP-1 Receptor Agonist Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait GLP-1 Receptor Agonist Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Kuwait GLP-1 Receptor Agonist Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Kuwait Glp-1 Receptor Agonist Market, 2021-2033 (US$M)
Kuwait glp-1 receptor agonist market statistics, by product, 2021-2033 (US$M)
